Table 1.
Patient and Treatment Characteristics
| Characteristic | Survivors (n = 121) |
Controls* (n = 43) |
P | ||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Male sex | 61 | 50.4 | 23 | 53.4 | .73 |
| Age at examination, years | .80 | ||||
| Median | 32.3 | 33.5 | |||
| Range | 14.6-58.9 | 14.8-56.9 | |||
| Race/ethnicity | |||||
| Non-Hispanic white | 45 | 37.2 | 22 | 51.2 | |
| Hispanic | 59 | 48.8 | 9 | 20.9 | |
| Other | 17 | 14.0 | 12 | 27.9 | < .01 |
| Body mass index ≥ 25 at examination | 55 | 45.5 | 19 | 44.2 | .89 |
| Currently employed part-time or full-time | 81 | 68.1 | 35 | 81.4 | .10 |
| Currently insured | 87 | 71.9 | 40 | 93.0 | < .01 |
| Exercise ≥ 3 days per week | 71 | 58.7 | 22 | 51.2 | .39 |
| Minutes per week of exercise | .30 | ||||
| Median | 150 | 120 | |||
| Range | 0-840 | 0-1,260 | |||
| Ever-smoker | 6 | 5.0 | 5 | 11.6 | .13 |
| Cardiomyopathy | 8 | 6.6 | 0 | .09 | |
| Diagnosis | |||||
| Lymphoma | 48 | 39.7 | — | — | |
| Hodgkin | 41 | 33.9 | — | — | |
| Non-Hodgkin | 7 | 5.8 | — | — | |
| Leukemia | 43 | 35.5 | — | — | |
| Acute lymphoblastic | 20 | 16.5 | — | — | |
| Acute myeloid | 17 | 14.0 | — | — | |
| Other | 6 | 5.0 | |||
| Solid malignancy | 30 | 24.8 | — | — | |
| Sarcoma | 13 | 10.7 | — | — | |
| Other | 17 | 14.1 | — | — | |
| Age at diagnosis, years | |||||
| Median | 16.5 | — | — | ||
| Range | 0.2-21.9 | ||||
| Time since diagnosis, years | |||||
| Median | 17.1 | — | — | ||
| Range | 6.3-40.1 | ||||
| Treatment details | |||||
| Cumulative dose of bleomycin, IU/m2 | |||||
| Median | 60 | — | — | ||
| Range | 30-360 | ||||
| Any | 42 | 34.7 | — | — | |
| Cumulative dose of busulfan, mg/m2 | |||||
| Median | 436 | — | — | ||
| Range | 115-1,102 | ||||
| Any | 15 | 12.4 | — | — | |
| Cumulative dose of BCNU or CCNU, mg/m2 | |||||
| Median | 450 | — | — | ||
| Range | 225-987 | ||||
| Any | 12 | 9.9 | — | — | |
| Chest radiation therapy, Gy | |||||
| Median | 13.2 | — | — | ||
| Range | 2-76 | ||||
| None | 32 | 26.4 | — | — | |
| ≤ 20 Gy | 60 | 49.6 | — | — | |
| > 20 Gy | 29 | 24.0 | — | — | |
| Surgery (any) | — | — | |||
| Lobectomy, wedge resection, metastectomy | 7 | 5.8 | — | — | |
| Hematopoietic cell transplantation | |||||
| None | 57 | 47.1 | — | — | |
| Autologous | 20 | 16.5 | — | — | |
| Allogeneic | 44 | 36.4 | — | — | |
| Overall treatment | — | — | |||
| Chemotherapy only | 31 | 25.6 | — | — | |
| Radiation therapy only | 32 | 26.4 | — | — | |
| Chemotherapy + radiation therapy | 58 | 48.0 | — | — | |
Abbreviations: BCNU, carmustine; CCNU, chloroethylcyclohexylnitrosourea.
*
Frequency-matched to cancer survivors by sex and age at participation.